IDH1 and glioblastoma: The PN signature correlates with a slightly less aggressive disease and increased response to anti-angiogenic treatment in patients with IDH-wild-type GBM, whereas the MES subgroup has been associated with radio-resistance and poorer prognosis [6, 7].